Hematologic Cancers News
Duvelisib improved PFS by more than 3 months compared with ofatumumab, the current standard of care, in relapsed or refractory CLL and SLL.
Investigators Report the Successful Allogeneic Transfer of Cytotoxic T Lymphocytes in Progressive Multifocal Leukoencephalopathy
BK-virus-specific T cells from a third-party donor were shown to successfully clear a related virus known to cause PML in 3 patients with different conditions.
Increased costs were found to be a result of more infections.
After antibiotic treatment during allogeneic hematopoietic stem cell transplantation, fecal transplantation was shown to restore patients' gut microbiota.
In patients with chronic lymphocytic leukemia, a lower ibrutinib dose appears to confer sufficient biological activity, but further study is needed.
The overlapping phenotypes of many hereditary anemias can make differential diagnosis and classification very difficult,
Hemophilic Joint Bleeding Promotes Vascular Remodeling, Rebleeding Independent of Hemostatic Correction
Hemophilic joint bleeding often leads to aberrant expression of alpha-smoot muscle actin, which can indicate vascular remodeling.
Emicizumab prophylaxis provides effective bleed prevention in people with hemophilia A with and without inhibitors.
A novel, von Willebrand factor-independent factor VIII therapy may allow patients with severe hemophilia A to pursue weekly dosing.
The study confirmed that recombinant and plasma-derived FVIII treatment products are associated with similar risk.
Although anovulation is the most common cause of heavy menstrual bleeding, an underlying hemostatic defect may also contribute to this menstrual problem.
Standard flow cytometry missed the detection of the CAR19 epitope on the surface of the leukemia cells.
The use of low-dose WBCT in multiple myeloma provided important information that helped guide patient management in 97% of the cases that were reviewed.
The use of rituximab for autoimmune thrombotic thrombocytopenic purpura did not significantly reduce acute iTTP relapses.
Results of the retrospective study require further confirmation.
First-degree relatives of patients with multiple myeloma were found to be at a higher risk of developing monoclonal gammopathy of undetermined significance.
Sequential dosing of brentuximab vedotin before and after standard doxorubicin, vinblastine, and dacarbazine showed a survival benefit in a phase II trial.
For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.
The safety and efficacy of investigational agent zanubrutinib is being evaluated in a head-to-head phase 3 trial in Waldenström macroglobulinemia.
Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma
- Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Role of miR-125a-5p Clarified in Bladder Cancer
- Bladder Cancer Clinical Features Linked to EGFR and HER-2 Expression
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- A Vegan Diet and Cancer
- The Optimal Neoadjuvant Regimen of Checkpoint Inhibitors in High-Risk Melanoma Is Unclear